We are live on ! Find out more

10x Genomics

TXG

Market cap $9.69B

74.39 USD

+4.28

6.1%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

75.35

+0.96

1.29%

1 day

6.1%

5 days

16.22%

1 month

28.28%

3 months

130.88%

6 months

345.72%

Year to date

347.59%

1 year

457.23%

5 years

-52.36%

10 years

41.02%

About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Employees: 1,178

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36.8%

Neutral 52.6%

Negative 10.5%

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

Zacks Investment Research

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Zacks Investment Research

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)

Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG's valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution.

10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)

Zacks Investment Research

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.

10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Up

10x Genomics Q2 Earnings Call Highlights

10x Genomics NASDAQ: TXG reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from a year earlier.

10x Genomics Q2 Earnings Call Highlights

10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript

10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript

Zacks Investment Research

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

See News Rankings

Price charts implemented using Lightweight Charts™